JP2002325853A - 哺乳類の過剰増殖組織を処理するための方法 - Google Patents

哺乳類の過剰増殖組織を処理するための方法

Info

Publication number
JP2002325853A
JP2002325853A JP2002061784A JP2002061784A JP2002325853A JP 2002325853 A JP2002325853 A JP 2002325853A JP 2002061784 A JP2002061784 A JP 2002061784A JP 2002061784 A JP2002061784 A JP 2002061784A JP 2002325853 A JP2002325853 A JP 2002325853A
Authority
JP
Japan
Prior art keywords
acetic acid
tumor
mammal
hyperproliferative tissue
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002061784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002325853A5 (cg-RX-API-DMAC7.html
Inventor
David A Bellnier
エイ ベルニアー ディヴィッド
Thomas J Dougherty
ジェイ ドハーティ トマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of JP2002325853A publication Critical patent/JP2002325853A/ja
Publication of JP2002325853A5 publication Critical patent/JP2002325853A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
JP2002061784A 2001-03-07 2002-03-07 哺乳類の過剰増殖組織を処理するための方法 Pending JP2002325853A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/801,163 US6495585B2 (en) 2001-03-07 2001-03-07 Method for treating hyperproliferative tissue in a mammal
US09/801163 2001-03-07

Publications (2)

Publication Number Publication Date
JP2002325853A true JP2002325853A (ja) 2002-11-12
JP2002325853A5 JP2002325853A5 (cg-RX-API-DMAC7.html) 2005-09-02

Family

ID=25180358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002061784A Pending JP2002325853A (ja) 2001-03-07 2002-03-07 哺乳類の過剰増殖組織を処理するための方法

Country Status (5)

Country Link
US (1) US6495585B2 (cg-RX-API-DMAC7.html)
EP (1) EP1238666B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002325853A (cg-RX-API-DMAC7.html)
AT (1) ATE295163T1 (cg-RX-API-DMAC7.html)
DE (1) DE60204067T2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053210B2 (en) 2002-07-02 2006-05-30 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US7166719B2 (en) 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
USRE39094E1 (en) 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
JP2002534483A (ja) * 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション 代謝性骨障害または骨転移のための治療的組成物
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US20020049247A1 (en) 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
WO2008147445A2 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
US8180444B2 (en) * 2007-06-22 2012-05-15 Biolitec Pharma Marketing Ltd Enhanced PhotoDynamic Therapy with immune system assist
US20110201678A1 (en) * 2008-10-17 2011-08-18 Masse Craig E Xanthenone-4-Acetic Acid Derivatives
CN109289048B (zh) * 2018-08-08 2021-05-25 南京工业大学 一种肿瘤血管阻断协同光治疗试剂及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
GB9308166D0 (en) * 1993-04-20 1993-06-02 Cancer Res Campaign Tech Cancer therapy

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7166719B2 (en) 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US7501509B2 (en) 2002-06-27 2009-03-10 Health Research, Inc. Water soluble tetrapyrollic photosensitizers for photodynamic therapy
US7820143B2 (en) 2002-06-27 2010-10-26 Health Research, Inc. Water soluble tetrapyrollic photosensitizers for photodynamic therapy
USRE43274E1 (en) 2002-06-27 2012-03-27 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US7053210B2 (en) 2002-07-02 2006-05-30 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives

Also Published As

Publication number Publication date
DE60204067D1 (de) 2005-06-16
EP1238666A3 (en) 2004-01-07
ATE295163T1 (de) 2005-05-15
DE60204067T2 (de) 2006-01-26
EP1238666B1 (en) 2005-05-11
EP1238666A2 (en) 2002-09-11
US20020128303A1 (en) 2002-09-12
US6495585B2 (en) 2002-12-17

Similar Documents

Publication Publication Date Title
US5257970A (en) In situ photodynamic therapy
KR100256853B1 (ko) 혈관 내막과 형성 증진을 억제하기위한 약제학적 조성물
Zhou et al. An ultrastructural comparative evaluation of tumors photosensitized by porphyrins administered in aqueous solution, bound to liposomes or to lipoproteins
Oluwajembola et al. Photosensitizers in photodynamic therapy: An advancement in cancer treatment
US20090192071A1 (en) Use of photodynamic therapy to enhance treatment with immuno-modulating agents
JP2002325853A (ja) 哺乳類の過剰増殖組織を処理するための方法
Tochner et al. Photodynamic therapy of ascites tumours within the peritoneal cavity
US5952329A (en) Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
JP2001511128A (ja) 水不溶性ポルフィリンの脂質錯体の凍結乾燥物
Kostron et al. Photodynamic therapy of malignant brain tumors: clinical and neuropathological results
Nishiwaki et al. New method of photosensitizer accumulation for photodynamic therapy in an experimental liver tumor
Mori et al. Photodynamic therapy for experimental tumors using ATX‐S10 (Na), a hydrophilic chlorin photosensitizer, and diode laser
US20080195032A1 (en) Photosensitizer formulations and their use
US4913907A (en) Porphycene anti-cancer agents and treatment methods
Cho et al. Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model
KR20120055604A (ko) 광역학 치료를 사용하는 암의 치료 방법
Selman et al. Copper benzochlorin, a novel photosensitizer for photodynamic therapy: effects on a transplantable urothelial tumor
Jori Photodynamic therapy of solid tumors
US5015478A (en) Porphycene anti-cancer agents and treatment methods
Land Porphyrin phototherapy of human cancer
Davis Photodynamic therapy in otolaryngology-head and neck surgery
CN108079293A (zh) 一种以修饰环肽rgd的石墨烯量子点为载体的复合药物、其制备方法及应用
Nakamura et al. Morphologic evaluation of the antitumor activity of photodynamic therapy (PDT) using mono-L-aspartyl chlorin e6 (NPe6) against uterine cervical carcinoma cell lines
US20040010218A1 (en) Photodynamic therapy for the enhancement of vascular permeability to aid in drug delivery to diseased tissues
WO2007086395A1 (ja) 光線力学的療法用キット

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090223